86 related articles for article (PubMed ID: 17597582)
1. Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity.
Baba T; Mori S; Matsumura N; Kariya M; Murphy SK; Kondoh E; Kusakari T; Kuroda H; Mandai M; Higuchi T; Takakura K; Fukuda MN; Fujii S
Biochem Biophys Res Commun; 2007 Aug; 360(2):363-9. PubMed ID: 17597582
[TBL] [Abstract][Full Text] [Related]
2. [Expression of lung resistant-related protein in ovarian cancer and its clinical significance].
Qian XL; Peng ZL; Liu SL; Wang H; Ni J
Ai Zheng; 2002 Dec; 21(12):1332-4. PubMed ID: 12520742
[TBL] [Abstract][Full Text] [Related]
3. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
4. The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer.
Sellar GC; Watt KP; Li L; Nelkin BD; Rabiasz GJ; Porteous DJ; Smyth JF; Gabra H
Int J Oncol; 2002 Nov; 21(5):929-33. PubMed ID: 12370737
[TBL] [Abstract][Full Text] [Related]
5. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
6. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
[TBL] [Abstract][Full Text] [Related]
7. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
8. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
9. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
[TBL] [Abstract][Full Text] [Related]
10. A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment.
Le Moguen K; Lincet H; Marcelo P; Lemoisson E; Heutte N; Duval M; Poulain L; Vinh J; Gauduchon P; Baudin B
Proteomics; 2007 Nov; 7(22):4090-101. PubMed ID: 17994630
[TBL] [Abstract][Full Text] [Related]
11. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.
Le Moguen K; Lincet H; Deslandes E; Hubert-Roux M; Lange C; Poulain L; Gauduchon P; Baudin B
Proteomics; 2006 Oct; 6(19):5183-92. PubMed ID: 16941573
[TBL] [Abstract][Full Text] [Related]
12. Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates.
Surowiak P; Materna V; Drag-Zalesinska M; Wojnar A; Kaplenko I; SpaczyĆski M; Dietel M; Zabel M; Lage H
Int J Gynecol Pathol; 2006 Apr; 25(2):131-9. PubMed ID: 16633061
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
14. Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT).
Sodek KL; Evangelou AI; Ignatchenko A; Agochiya M; Brown TJ; Ringuette MJ; Jurisica I; Kislinger T
Mol Biosyst; 2008 Jul; 4(7):762-73. PubMed ID: 18563251
[TBL] [Abstract][Full Text] [Related]
15. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome.
Pinto D; Pereira D; Portela C; da Silva JL; Lopes C; Medeiros R
Biochem Biophys Res Commun; 2005 Oct; 335(4):1173-8. PubMed ID: 16112085
[TBL] [Abstract][Full Text] [Related]
16. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
17. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
18. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.
Chan DW; Liu VW; Tsao GS; Yao KM; Furukawa T; Chan KK; Ngan HY
Carcinogenesis; 2008 Sep; 29(9):1742-50. PubMed ID: 18632752
[TBL] [Abstract][Full Text] [Related]
19. Proteins' promise--progress and challenges in ovarian cancer proteomics.
Koehn H; Oehler MK
Menopause Int; 2007 Dec; 13(4):148-53. PubMed ID: 18088525
[TBL] [Abstract][Full Text] [Related]
20. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma.
Saga Y; Ohwada M; Suzuki M; Konno R; Kigawa J; Ueno S; Mano H
Oncol Rep; 2008 Dec; 20(6):1299-303. PubMed ID: 19020706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]